Home

Articles from Recor Medical

Recor Medical Statement on CMS National Coverage Analysis of Renal Denervation for the Treatment of Hypertension
Palo Alto, CA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced that the Centers for Medicare and Medicaid Services (CMS) have begun a National Coverage Analysis (NCA) of Renal Denervation (RDN), a medical device-based treatment for hypertension.
By Recor Medical · Via GlobeNewswire · January 13, 2025
Recor Medical announces CMS Grant of Transitional Pass-Through (TPT) Payment for Recor’s Paradise Ultrasound Renal Denervation System for the Treatment of Uncontrolled Hypertension
The Paradise Ultrasound Renal Denervation (uRDN) system becomes the first and only ultrasound-based renal denervation (RDN) therapy to be granted a distinct category and device code for incremental Outpatient Transitional Pass-through (TPT) payment by CMS, recognizing the differentiation of Paradise uRDN system in facilitating Medicare fee-for-service beneficiary access to new and innovative medical technologies.
By Recor Medical · Via GlobeNewswire · November 1, 2024
Recor Medical Responds to the American Heart Association’s (AHA) Scientific Statement on Renal Denervation for the Treatment of Hypertension
Statement from the AHA in support of Renal Denervation as a hypertension therapy option provides reinforcement that the treatment can have a meaningful positive impact on the wellbeing of people with resistant or uncontrolled high blood pressure.
By Recor Medical · Via GlobeNewswire · August 19, 2024
CMS Approves Additional Payment for Recor Medical’s Paradise™ Ultrasound Renal Denervation System in Hospital Inpatient Cases
Availability of the New Technology Add-on Payment (NTAP) will improve access to innovative ultrasound hypertension therapy for patients across the country
By Recor Medical · Via GlobeNewswire · August 12, 2024
First Patients Treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS) for the Treatment of Uncontrolled Hypertension with Ultrasound Renal Denervation
Durham VA Health Care System in North Carolina is the first site in US to enroll and treat patients in the study collecting real-world data on long-term safety and effectiveness of the Paradise® Ultrasound Renal Denervation System.
By Recor Medical · Via GlobeNewswire · July 25, 2024
Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide
Palo Alto, CA, May 17, 2024 (GLOBE NEWSWIRE) -- Hypertension, or high blood pressure, affects nearly half of all Americans and more than one billion people worldwide.  Hypertension is known as the “silent killer” because many people do not know they have it and, over time, it can lead to serious health issues. Hypertension is the number one contributor to the burden of human disease globally, has been associated with a five-year reduction in life expectancy and is a major risk factor for heart disease, stroke, heart attacks and other serious health problems.
By Recor Medical · Via GlobeNewswire · May 17, 2024
Recor Medical Announces First Cases of Paradise Ultrasound Renal Denervation Therapy in the United Arab Emirates
l Qassimi Hospital Sharjah becomes first in the Middle East to treat patients with innovative new device-based option to help reduce blood pressure.
By Recor Medical · Via GlobeNewswire · April 18, 2024
Recor Medical and Otsuka Medical Devices Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise™ Ultrasound Renal Denervation System for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) announce the U.S. Food and Drug Administration (FDA) Circulatory Systems Devices Panel of the Medical Devices Advisory Committee met to discuss the pre-market approval application (PMA) for the Paradise™ Ultrasound Renal Denervation (RDN) system, indicated to reduce blood pressure in patients with hypertension. The overall vote from the committee was favorable that there was sufficient data to support the use of the device in patients with uncontrolled hypertension.
By Recor Medical · Via Business Wire · August 22, 2023